Bionor Rises Most in 15 Months on AIDS Drug Study: Oslo Mover
This article is for subscribers only.
Bionor Pharma ASA, the Norwegian developer of an experimental AIDS treatment, jumped the most in 15 months after it confirmed the injection fought HIV in a study and described plans to develop a drug it once gave up for dead.
Bionor rose 37 percent to 3.45 kroner in Oslo trading, giving the company a market value of 623 million kroner ($108 million). The gain was the biggest since Nov. 18, 2010. More than 21 million shares were traded, more than 20 times the daily average for the past six months and the most in a day since Dec. 13, 2010.